3 edition of Craniofacial effects of alendronate treatment in growing osteogenesis imperfecta mice. found in the catalog.
Craniofacial effects of alendronate treatment in growing osteogenesis imperfecta mice.
Jonathan E. Britton
Written in English
Bisphosphonates have shown promise in reducing fractures in children with osteogenesis imperfecta (OI). To date, effects of these drugs on the growing craniofacial skeleton have not been investigated. To address this, alendronate (ALN) was evaluated in the growing oim/oim mouse, a model of moderate-to-severe OI. Wildtype (+/+) and oim/oim mice received saline or ALN at a dosage of 26 mug ALN/kg/day from 6-12 weeks of age. Skulls (n=49) were scanned at 12 weeks with microCT to create 3D reconstructions. Cranial and mandibular landmarks were digitized and statistical shape analysis methods compared cranial and mandibular size and shape between groups. Back-scattered electron imaging of the spheno-occipital synchondrosis evaluated drug effects on bone quality. oim/oim mice exhibited significant skull dysmorphology with parallels to human OI. The anti-resorptive activity of ALN does not appear to compromise craniofacial growth. ALN treatment normalized FM morphology in oim/oim mice through improvements in skull bone quality.
|The Physical Object|
|Number of Pages||104|
Bargman R, Huang A, Boskey AL, Raggio C, Pleshko N. RANKL inhibition improves bone properties in a mouse model of osteogenesis imperfecta. Connect Tissue Res Apr;51(2) Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse Bone, Vol. 36, No. 1 Bisphosphonate treatment affects trabecular bone apparent modulus through micro-architecture rather than matrix properties.
Cyclical intravenous pamidronate treatment affects metaphyseal modeling in growing patients with osteogenesis imperfecta. J Bone Miner Res. ; – [ PubMed ] Bisphosphonates are currently used for the treatment of osteogenesis imperfecta (Barros et al., ; Bishop et al., Msx2 -/- transgenic mice develop compound amelogenesis imperfecta, dentinogenesis imperfecta and periodental osteopetrosis. Effects of alendronate on tooth eruption and molar root formation in young growing rats.
ronate, a more potent bisphosphonate than pamidronate, in OI. Materials and Methods: Three patients (age, 3–7 years; mean, 5 years) (one case, type III; 2 cases, type IV) have been given alendronate (– mg/kg per day orally) for 2 years. Number of fractures, ambulation, height growth, and bone mineral density by dual-energy x-ray absorptiometry (DXA) were followed up. Results: Bone. Frank Rauch, Yeqing Geng, Lisa Lamplugh, Bahareh Hekmatnejad, Marie-Hélène Gaumond, Janice Penney, Yojiro Yamanaka and Pierre Moffatt, Crispr-Cas9 engineered osteogenesis imperfecta type V leads to severe skeletal deformities and perinatal lethality in mice, Bone, /, , (), ().
Eighteenth Century: A Current Bibliography. New Series, 3: For 1977. Ed by R.R. Allen. Continues
objectives of macro-economic policy [by] Ajit K. Dasgupta [and] A.J. Hagger.
Frontiers of multifunctional nanosystems
Catalog of U.S. government meteorological research and test facilities
Collection of facts and documents relative to the project of a bridge from South Street in Boston to Dorchester Neck, and the annexation of that peninsula to the town of Boston
Ontonagon Harbor, Michigan. Letter from the Secretary of War, transmitting, with a letter from the Chief of Engineers, report of examination of Ontonagon Harbor, Michigan.
Canadian corporation precedents
The Palladium of conscience ...
Fauna of the Kimmswick limestone of Missouri and Illinois
Culm Valley Light Railway
Basic statistics for business and economics
For love of birds.
Modern American drinks
chat about America.
Cat body language
Bisphosphonates have been reported to decrease the number of fractures in children with osteogenesis imperfecta (OI). The current study sought to further explore bisphosphonate-associated bone changes in OI by investigating the effects of alendronate (ALN) treatment on bone mechanical and material properties in osteogenesis imperfecta (oim/oim) and wild-type (+/+) mice treated with Cited by: Misof BM, Roschger P, Baldini T, Raggio CL, Zraick V, Root L, Boskey AL, Klaushofer K, Fratzl P, Camacho NP.
Differential effects of Aln treatment on bone from growing osteogenesis imperfecta and wild-type mouse. Bone. ; –Cited by: OBJECTIVE: Osteogenesis imperfecta (OI) is a group of inherited diseases characterized by reduced bone mass, recurrent bone fractures, and progressive bone deformities.
Here, we evaluate the efficacy and safety of long-term treatment with alendronate in a large sample of Chinese children and adolescents with OI.
They are also used in young patients with diseases like osteogenesis imperfecta or juvenile osteoporosis. our objective was to evaluate the effect of alendronate (ALN) on growing animals Cited by: 4.
1. Introduction. Osteogenesis imperfecta (OI) is a congenital disorder that is characterized by low bone mass and recurrent bone fractures .It is generally caused by autosomal dominant mutations in COLIA1 or COLIA2 gene which encodes type I collagen .These heterozygous mutations can lead to abnormal collagen synthesis and result in decreased bone mass and strength, Author: Yi Liu, Mingyan Ju, Zihan Wang, Jiaci Li, Chenyi Shao, Ting Fu, Yaqing Jing, Yuxia Zhao, Zhe Lv, Gua.
Misof B.M, Roschger P, Baldini T, Raggio C.L, Zraick V, Root L., et al. Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse. Bone. ;36(1) CrossRef. Bisphosphonates (BPs) are widely used for treatment of osteogenesis imperfecta (OI).
However, prolonged use may be associated with suppression of bone turnover, the. Demetris Delos, Xu Yang, Benjamin F.
Ricciardi, Elizabeth R. Myers, Mathias P.G. Bostrom and Nancy Pleshko Camacho, The effects of RANKL inhibition on fracture healing and bone strength in a mouse model of osteogenesis imperfecta, Journal of Orthopaedic Research, 26, 2, (), ().
Evans K, Lau S, Oberbauer A, Martin R. Alendronate affects long bone length and growth plate morphology in the oim mouse model for osteogenesis imperfecta. Bone. ;32(3)– Misof BM, Roschger P, Baldini T, et al. Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse.
Uveges TE, Kozloff KM, Ty JM, et al. Alendronate treatment of the Brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation.
J Bone Miner Res. ; 24 (5)– [PMC free article] [Google Scholar]. Camacho NP, Raggio CL, Doty SB, et al. A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta. Calcif Tissue Int ; Crossref; Web of. Comment on: Strontium Ranelate Reduces the Fracture Incidence in a Growing Mouse Model of Osteogenesis Imperfecta C.
Shi et al, JBMR 31(5) ‐, Article Aug The aim of this study was to identify the craniofacial characteristics of 16 osteogenesis imperfecta (OI) patients, 10 males and 6 females, aged 7–15 years.
The control group comprised Chinese children from 6 to 18 years of age. Comparable outcomes in fracture reduction and bone properties with RANKL inhibition and alendronate treatment in a mouse model of osteogenesis imperfecta.
Osteoporos. Int. –, Panigrahi I, Das RR, Sharda S, et al. Response to zolendronic acid in children with type III osteogenesis imperfecta. J Bone Miner Metab ; Vuorimies I, Toiviainen-Salo S, Hero M, et al.
Zoledronic acid treatment in children with osteogenesis imperfecta. Horm Res Paediatr ; Thomas E Uveges, Kenneth M Kozloff, Jennifer M Ty, Felicia Ledgard, Cathleen L Raggio, Gloria Gronowicz, Steven A Goldstein, Joan C Marini, Alendronate Treatment of the Brtl Osteogenesis Imperfecta Mouse Improves Femoral Geometry and Load Response Before Fracture but Decreases Predicted Material Properties and Has Detrimental Effects on.
Alendronate Treatment of the Brtl Osteogenesis Imperfecta Mouse Improves Femoral Geometry and Load Response Before Fracture but Decreases Predicted Material Properties and Has Detrimental Effects on Osteoblasts and Bone Formation Thomas E.
Uveges,1,2,3 Kenneth M. Kozloff,3,4 Jennifer M. Ty,1,5 Felicia Ledgard,6 Cathleen L. Raggio,7. Osteogenesis imperfecta (OI), also known as brittle bone disease, is a group of genetic disorders that mainly affect the bones. It results in bones that break easily. The severity may be mild to severe.
Other symptoms may include a blue tinge to the whites of the eye, short height, loose joints, hearing loss, breathing problems and problems with the teeth. Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment.
Bone. ;– Roschger A, Roschger P, Keplingter P, et al. Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta. Bone. ;– Bruna Pinheiro, Marina B. Zambrano, Ana Paula Vanz, Evelise Brizola, Liliane Todeschini de Souza, Têmis Maria Félix, Cyclic pamidronate treatment for osteogenesis imperfecta: Report from a Brazilian reference center, Genetics and Molecular Biology, /gmb, ().
Fracture Healing with Alendronate Treatment in the Brtl Model of Osteogenesis Imperfecta Author: Jeff Meganck, Michelle Caird, Dana Begun, Aaron Swick, Joan Marini, Steve Goldstein Created Date: 1/6/ PM.Alendronate treatment of the brtl osteogenesis imperfecta mouse improves femoral geometry and load response before fracture but decreases predicted material properties and has detrimental effects on osteoblasts and bone formation.
J Bone Miner Res (); 24(5)– /jbmr Crossref, Medline, ISI, Google Scholar; Camacho NP, Raggio CL, Doty SB, Root L, Zraick V, Ilg WA, et al. A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta. Calcif Tissue Int. ;69(2)– PubMed CrossRef Google Scholar.